Evolutionary Approaches to Prolong Progression-Free Survival in Breast Cancer
- 15 December 2012
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 72 (24) , 6362-6370
Abstract
Many cancers adapt to chemotherapeutic agents by upregulating membrane efflux pumps that export drugs from the cytoplasm, but this response comes at an energetic cost. In breast cancer patients, expression of these pumps is low in tumors before therapy but increases after treatment. While the evolution of therapeutic resistance is virtually inevitable, proliferation of resistant clones is not, suggesting strategies of adaptive therapy. Chemoresistant cells must consume excess resources to maintain resistance mechanisms, so adaptive therapy strategies explicitly aim to maintain a stable population of therapy-sensitive cells to suppress growth of resistant phenotypes through intratumoral competition. We used computational models parameterized by in vitro experiments to illustrate the efficacy of such approaches. Here, we show that low doses of verapamil and 2-deoxyglucose, to accentuate the cost of resistance and to decrease energy production, respectively, could suppress the proliferation of drug-resistant clones in vivo. Compared with standard high-dose-density treatment, the novel treatment we developed achieved a 2-fold to 10-fold increase in time to progression in tumor models. Our findings challenge the existing flawed paradigm of maximum dose treatment, a strategy that inevitably produces drug resistance that can be avoided by the adaptive therapy strategies we describe. Cancer Res; 72(24); 6362–70. ©2012 AACR.Keywords
All Related Versions
This publication has 37 references indexed in Scilit:
- Uptake of 2-NBDG as a method to monitor therapy response in breast cancer cell linesBreast Cancer Research and Treatment, 2010
- The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumorsBMC Cancer, 2009
- Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myelomaLeukemia, 2009
- Adaptive TherapyCancer Research, 2009
- Membrane microparticles mediate transfer of P-glycoprotein to drug sensitive cancer cellsLeukemia, 2009
- The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug ResistanceClinical Cancer Research, 2008
- Is cell competition relevant to cancer?Nature Reviews Cancer, 2008
- A real-time method of imaging glucose uptake in single, living mammalian cellsNature Protocols, 2007
- Expression of P-glycoprotein in breast cancer tissue and in vitro resistance to doxorubicin and vincristineEuropean Journal of Cancer and Clinical Oncology, 1991
- Glycolysis in P‐glycoprotein‐overexpressing human tumor cell lines Effects of resistance‐modifying agentsFEBS Letters, 1989